Cellular Immunotherapy Market Insights 2025-2034: Growth Forecast and Strategic Priorities

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Cellular Immunotherapy Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
Over the past few years, the cellular immunotherapy market size has witnessed substantial growth. It is anticipated to escalate from $5.72 billion in 2024 to $6.56 billion in 2025, reflecting a compound annual growth rate (CAGR) of 14.7%. The development in the historic era is a result of progresses in cancer treatment procedures, triumph in clinical trials, regulatory authorizations, as well as an increase in the occurrence of targeted diseases.

Cellular Immunotherapy Market Size Forecast: What's the Projected Valuation by 2029?
The market size for cellular immunotherapy is projected to experience a substantial increase in the coming years. It is projected to expand to a valuation of "$11.03 billion by 2029, registering a CAGR of 13.9%. This projected growth within the prediction period can be credited to the expansion of the therapy to solid tumours, advancements in manufacturing, development in healthcare infrastructure, and increased funding for research. Some key trends for the prediction period include investments in research and development, data from clinical trials, and combined therapeutic approaches.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

What Are the Drivers Transforming the Cellular Immunotherapy Market?
The cellular immunotherapy market is predicted to expand due to increasing research and successful trials. Companies are directing their efforts towards the creation of new cellular immunotherapies for various diseases. In June 2022, the Cancer Research Institute, a US-based nonprofit organization wholly dedicated to immunotherapy development for complete cancer prevention, treatment and elimination, released a report. This report showed a worldwide immuno-oncology pipeline of 2,756 active cell therapy drugs in April 2022, a 36% increase from 2021's landscape analysis that found 2,031 such agents. Although this growth is slightly slower compared to the 43% in the prior year, the rapid increase in developing cellular immunotherapy at clinical and preclinical stages in 2020 compared to 2019, is anticipated to amplify the reach of cellular immunotherapy. This trend will likely result in higher revenues contributing to the advancement of the cellular immunotherapy market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Cellular Immunotherapy Market?
Businesses within the cellular immunotherapy industry are redirecting their efforts to the creation of off-the-shelf allogeneic therapies, aimed at enhancing cancer treatment. Unlike autologous therapy that uses the patient's cells, these therapies are derived from donors' cells. They offer benefits like cost-efficiency, rapid production on a large scale, and quality regulation. For instance, in May 2022, the US Food and Drug Administration (FDA) granted accelerated approval for Kymriah (tisagenlecleucel) by Novartis AG, a Swiss pharmaceutical firm specializing in drug discovery, development, manufacturing, and sales. This move was made after the therapy showed promising results following two or more lines of systemic therapy, specifically for adults with relapsed or refractory (r/r) follicular lymphoma (FL). Moreover, the US firm Acepodia, known for its advanced cell immuno-technology, is set to commence a phase 1 clinical trial in August 2020. This trial will examine ACE1702, an off-the-shelf NK cell therapy, to see its effects on the treatment of solid tumors.

Which Segments in the Cellular Immunotherapy Market Offer the Most Profit Potential?
The cellular immunotherapy market covered in this report is segmented -

1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy
2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications
3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications

Subsegments:
1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy, Other TIL Therapy
2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy, Other Engineered TCR Therapy
3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies, Other CAR T Cell Therapy
4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications, Other NK Cell Therapy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=3435&type=smp

Which Firms Dominate the Cellular Immunotherapy Market by Market Share and Revenue in 2025?
Major companies operating in the cellular immunotherapy market include Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation

Which Regions Offer the Highest Growth Potential in the Cellular Immunotherapy Market?
North America was the largest region in the cellular immunotherapy market in 2024. The regions covered in the cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3435

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert: Saumya Sahay: Americas +1 310-496-7795: Asia +44 7882 955267 & +91 8897263534: Europe +44 7882 955267: Email: saumyas@tbrc.info: The Business Research Company - www.thebusinessresearchcompany.com: Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.